Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 13

Results For "BAL-Pharma"

491 News Found

Glenmark launches nutrition program to fight malnutrition in Philippines
News | March 26, 2025

Glenmark launches nutrition program to fight malnutrition in Philippines

This program, titled "Food Supplementation and Capacity Building Support for Improved Nutrition in Malinao, Aklan," aligns with the country’s national health


Merck inks $200 million deal for Hengrui's midstage heart disease drug
News | March 26, 2025

Merck inks $200 million deal for Hengrui's midstage heart disease drug

Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region


Nanomi receives CMO Award for Life Science Leadership in drug delivery
News | March 22, 2025

Nanomi receives CMO Award for Life Science Leadership in drug delivery

Nanomi's pioneering approach in drug delivery has set new benchmarks in the industry, and this award serves as a motivation to continue its mission to revolutionize healthcare


Lupin bags EcoVadis Silver Medal for sustainability excellence
Sustainability | March 21, 2025

Lupin bags EcoVadis Silver Medal for sustainability excellence

Over the last two years, Lupin has showcased exceptional improvement in its EcoVadis scoring


BrePco Biopharma and Piramal Critical Care announce MHRA approval for Neoatricon in UK
Drug Approval | March 21, 2025

BrePco Biopharma and Piramal Critical Care announce MHRA approval for Neoatricon in UK

PCC has secured the commercialization rights for the EU, UK, and Norway and will be responsible for distributing Neoatricon in these regions


Glenmark Pharma launches Empagliflozin and its fixed-drug combinations in India
News | March 13, 2025

Glenmark Pharma launches Empagliflozin and its fixed-drug combinations in India

Empagliflozin and its Fixed Drug Combinations (FDCs) have been launched under the brand names Glempa, Glempa –L and Glempa-M


Syngene acquires first US biologics facility for $36.5 million
News | March 11, 2025

Syngene acquires first US biologics facility for $36.5 million

Overall investment in the US facility is estimated around US$50 million


Lupin Launches Rivaroxaban Tablets USP, 2.5mg in US
Drug Approval | March 07, 2025

Lupin Launches Rivaroxaban Tablets USP, 2.5mg in US

Rivaroxaban Tablets USP, 2.5 mg, is bioequivalent to Xarelto® Tablets, 2.5 mg of Janssen Pharmaceuticals


Lupin secures a place in S&P Global Sustainability Yearbook 2025
Sustainability | February 28, 2025

Lupin secures a place in S&P Global Sustainability Yearbook 2025

Yearbook members are selected basis their S&P Global 2024 Corporate Sustainability Assessment score


Zydus Lifesciences to launch protection against new strain of influenza virus
News | February 27, 2025

Zydus Lifesciences to launch protection against new strain of influenza virus

VaxiFlu-4 is being marketed by Zydus Vaxxicare-a division of the group focussing on preventives